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Abstract: The use of intravascular ultrasound (IVUS) to improve acute angiographic results was already shown in the 
prestent era. Various studies demonstrated the efficacy of IVUS in balloon sizing and estimating the extent of positive 
remodeling. With the introduction of drug-eluting stents (DES) the rate of restenosis has been significantly reduced but a 
new concern, the risk of stent thrombosis, has emerged. The association of stent underexpansion with stent thrombosis 
was observed for bare metal stents (BMS) and DES. Until now, the criteria for IVUS optimization used in different 
studies have relied on distal reference or on mean reference vessel for stent or postdilatation balloon sizing. Furthermore, 
an important recent innovation not available in previous studies is the use of noncompliant balloons to perform high 
pressure post-dilatation. Universal and easily applicable IVUS criteria for optimization of stent implantation as well as 
randomized studies on IVUS-guided DES implantation are necessary to minimize stent malapposition and 
underexpansion, which in turn can positively influence the rates of stent restenosis and thrombosis. 
Keywords: Intravascular ultrasound, drug-eluting stents, stent malapposition, stent underexpansion, percutaneous coronary 
intervention, restenosis, stent thrombosis. 
INTRODUCTION 
The introduction of drug-eluting stents (DES) has reduced 
the rate of restenosis and the need for repeat 
revascularization in comparison to bare metal stents (BMS) 
[1-4]. The promise of stents with minimal or almost no 
restenosis were eagerly awaited and rapidly adopted by the 
interventional cardiology community. It was initially 
believed that the strong antirestenotic effects of the 
antiproliferative drug coatings would be sufficient to 
eradicate the problem of in-stent restenosis that had plagued 
BMS. However, as DES implantation was extended into 
more complex lesion and patient subsets than previously 
studied in large randomized trials [1-3, 5], it became clear 
the optimal DES implantation may be as important if not 
more with these new devices. The efficacy of DES appears 
to be related not only to the combination of drug and 
polymer kinetics but also to how well the device is deployed 
in the coronary artery. Suboptimal stent implantation (in 
particular stent underexpansion) has become recognized as 
an important risk factor not only for DES failure (restenosis) 
but also for the more serious and rare event of stent 
thrombosis [6, 7].  
Why IVUS-guided stenting? 
  The use of intravascular ultrasound (IVUS) to improve 
lesion dilation and the acute angiographic result was already 
shown in the pre-stent era. Various studies demonstrated the 
efficacy of IVUS in balloon sizing and estimating the extent  
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of positive remodeling [8]. Small observational studies in the 
BMS era suggested the benefits of a larger stent cross-
sectional area (CSA) and higher postdilation pressures with 
IVUS guidance, on better stent apposition and restenosis 
rates [9-12]. Until now, the criteria for IVUS optimization 
used in different studies have relied on distal vessel 
reference or on the mean reference vessel size for stent or 
postdilatation balloon sizing. This reduces the potential to 
optimally increase the lumen size in long lesions, 
overlapping stents and in vessels with distal tapering. In 
addition, these criteria do not take advantage of vessel 
remodeling which may allow the operator to attain a larger 
final stent CSA. Also the actual results and differences in 
final minimal lumen diameter (MLD) achieved with IVUS 
compared to angiographic guidance has been small in 
previous studies. Furthermore, an important recent 
innovation not available in previous studies that may be 
having a significant contribution on optimal stent 
implantation is the use of noncompliant balloons to perform 
high pressure postdilatation. Up to now, there is no 
randomized study on IVUS-guided DES implantation. 
Consequently, IVUS guidance has played a limited role in 
the current clinical practice due a lack of clear demonstrable 
clinical benefit. IVUS guided stent implantation with modern 
noncompliant balloons and improved criteria for optimal 
stent expansion would probably result in an immediate result 
of better stent expansion and implantation that should 
translate into a long-term clinical benefit. To test this 
hypothesis, a new multicenter randomized trial, the 
Angiographic Versus IVUS Optimization (AVIO), has been 
designed by our group. 
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Previous Trials on IVUS-Guided Stenting 
  A comparison of the most important studies on IVUS 
published before the stent era and after the introduction of 
BMS and DES, may be give a better understanding of the 
diversity and lack of precision of the IVUS criteria most 
commonly used for optimal stent implantation. It is 
interesting to notice a continuous change of IVUS criteria 
both for balloon sizing and optimal result of percutaneous 
transluminal coronary angioplasty (PTCA) with or without 
stent implantation. Honing of the technique and increasing 
understanding of the information obtainable from ultrasound 
exploration of coronary arteries were reflected in 
modifications of IVUS criteria which matured with the 
experience of the operators. A continuous increase in acute 
lumen gain has been observed in several randomized and 
observational studies on coronary stenting. This reflects the 
learning curve of optimizing stent implantation and 
expansion which was triggered by the concept “the bigger 
the better” and the need for additional imaging modalities to 
avoid stent thrombosis and improve long-term outcomes 
[13]. 
 Numerous
 studies have clearly established that a major 
determinant of
  the rate of restenosis was the % diameter 
stenosis (DS) or MLD achieved after intervention, which 
resulted in the "bigger is better" doctrine [14, 15]. However,
 
attempts to improve the procedural results of PTCA by the 
use
 of balloons larger than the angiographic vessel diameter
 
have resulted in unacceptably high rates of major arterial 
dissection, myocardial
  infarction, and emergent bypass 
surgery [16]. The rate of these complications was 
significantly reduced by the use of IVUS. 
 In  the  Clinical Outcomes with Ultrasound Trial 
(CLOUT) trial [8], IVUS was used to guide the selection of 
balloons traditionally
  considered oversized on the basis of 
the degree of plaque burden
  and vessel expansion in the 
target lesion and adjacent reference segments. IVUS was 
performed after balloon angioplasty to establish MLD and 
minimal vessel diameter (MVD) and calculate the balloon 
size for an extra dilatation after balloon angioplasty 
according to the formula: [MLD + MVD] * 0.5 (mm). If the 
size of the balloon used for the angioplasty was already 
comparable to the size calculated according to the IVUS-
based formula, no further dilatation was necessary. The 
median increase of the balloon size was 0.5 mm. A 
significant decrease in the
  mean angiographic DS was 
observed after IVUS balloon “oversizing” compared to 
angiographic evaluation (18±14% vs. 28±15%), with a 
corresponding increase in angiographic minimal lumen area 
(MLA, 1.95±0.49 to 2.21±0.47) and IVUS MLA (3.16±1.04 
to 4.52±1.14
 mm
2, p<0.001). The incidence of angiographic 
dissection
  was not increased by IVUS-guided balloon 
upsizing (37% vs. 40%, p=0.67), emphasizing the role of 
IVUS guidance in the selection of the
 "oversized" balloon 
diameter. 
  The CLOUT study criteria for balloon sizing were also 
used in the single-center, prospective randomized Strategy 
and Intracoronary Ultrasound-Guided PTCA and 
Stenting (SIPS) trial [17]. IVUS measurements were done 
after PTCA (without stent implantation in 50.3% of the 
IVUS vs. 50.5% of the angio-guided group, p=0.96). Even 
though no significant differences were observed in the 
primary endpoint (MLD at 6-month angiographic follow-up: 
1.71±0.09 for IVUS vs. 1.56±0.9 mm for angio-guided, 
p=0.19), the acute postprocedural result (i.e. acute gain) was 
significantly improved (acute gain in the IVUS 1.85±0.72 vs. 
1.67±0.76 mm in the angio-guided group, p = 0.02). This 
acute improvement in MLD was associated with lower 
events, and in particular a reduction in clinically driven 
target lesion revascularization (TLR) at 2 years in the IVUS 
guided group (21% vs. 43%, p = 0.02). 
  In 1995, our group [13] documented by IVUS that 
majority of stents were inadequately expanded despite an 
optimal angiographic final result. After IVUS optimization, 
the intra-stent MLA increased from 6.6 to 8.8 mm
2. 
Similarly, other small observational trials of Albiero et al. 
[9] and Blasini et al.[10] documented the usefulness of IVUS 
in assessing appropriate stent expansion. 
  Optimal stent apposition and expansion had been already 
pointed out by numerous authors [9, 10, 13] as factors that 
might improve acute and long-term outcomes after stent 
implantation, but a clear IVUS definition was lacking. The 
observational  Multicenter Ultrasound Stenting in 
Coronaries (MUSIC) trial [11] was the first study that 
established IVUS criteria for optimal stent implantation (see 
Table 1). IVUS was utilized to assess complete apposition of 
the stent in all its length against the vessel wall as well as its 
symmetric expansion. Moreover, numerical criteria, 
expressed in % of MLA for the reference segment or 
minimal MLA in mm
2  (see Table 1) were created and 
subsequently followed in other IVUS-guided stenting 
studies. In comparison with the BENESTENT I [14] and 
BENESTENT II [18] studies, the data from the MUSIC trial 
confirmed that IVUS-guided stent implantation improved 
immediate angiographic outcomes (post-MLD, 2.90±0.36) 
which, in turn might explain the favorable clinical and 
angiographic outcomes at 6 months (the lowest TLR 5.7% 
and restenosis rate 9.7% with the largest MLD 2.12±0.67). A 
unique feature of MUSIC was that patients were treated only 
with single antiplatelet therapy with aspirin (no dicumarols 
or thienopyridines) after stent implantation, despite which 
stent thrombosis was documented in only 2 patients (1.3%). 
 In  the  Balloon Equivalent to Stent (BEST) Study [19], 
IVUS-guided balloon angioplasty was randomly compared 
with systematic stenting. A total of 132 patients were 
randomized to IVUS-guided balloon angioplasty, and 122 
were randomized to stenting. In the aggressive PTCA group, 
crossover to stent was needed in 58 patients (44%) because 
of dissection (18%) or an unsatisfactory result (26%). The 
balloon diameter used for aggressive PTCA was determined 
on the basis of IVUS measurements of mean vessel diameter 
(determined by external elastic membrane). The balloon 
inflation followed the compliance curve to obtain the desired 
diameter. The final MLD was larger in the stent group 
(2.75±0.49 vs. 2.55±0.49 mm with aggressive PTCA, 
p=0.013), but patients from the aggressive PTCA group who 
crossed over to stent had similar immediate results as those 
in the stent group (2.69±0.49 vs. 2.75±0.49 respectively, 
p=0.65). At 6-months, the restenosis rate was 16.8±6.7% in 
the aggressive PTCA group vs. 18.1±7.0% in the stent group 
(p=0.70). Also angiographic MLD did not differ 
significantly between the study groups (1.97±0.72 vs. 
2.03±0.72 mm, PTCA and stent respectively, p=0.38).  80    Current Cardiology Reviews, 2009, Vol. 5, No. 2  Rogacka et al. 
 
Table 1.   Comparison of Studies with IVUS Optimization of Percutaneous Transluminal Coronary Angioplasty (PTCA) with or 
without Stent Implantation 
Results 
  Balloon Sizing (BS)  IVUS Criteria 
Angiographic IVUS 
Study Design 
CLOUT [8] 
1997 
(MLD+MVD)*0.5 
in the proximal and 
distal segment 
If PTCA balloon size was 
already equal to BS obtained 
according to the formula, no 
further dilatation performed 
(27% lesions) 
MLA 2.21±0.47
 
Acute gain 0.20 
MLA 
4.52±1.14, p<0.001 
Acute gain 
0.26, p<0.001 
155 pts; 
observational 
study; only 
postprocedural 
endpoints 
MLD 2.90±0.36; 
Acute gain 1.79±0.39 
MLD 
3.10±0.40 
 
MUSIC [11] 
1998 
IVUS used for 
evaluation of 
appropriate stent 
apposition.  7 mo TLR: 5.7% 
161 pts; 
observational 
MLD 2.38±0.67; 
Acute gain 1.67±0.76 
MLD 
2.49±0.66, p=0.12; 
Acute gain 1.85±0.72; 
p=0.02 
2 years clinical FU: clinically driven TLR  SIPS [17] 
2000 
(MLD+MVD)*0.5 
in the prox e distal 
segment 
1. Complete apposition against 
the vessel wall of the entire 
stent. 
2. a) MLA90% of the average 
reference lumen area or 100% 
of lumen area of the 
reference segment with the 
lowest lumen area. 
b) MLA >9.0 mm2. 
c) MLA 80% of the average 
reference lumen area or 90% 
of lumen area of the 
reference segment with the 
lowest lumen area. 
3. Symmetric stent expansion. 
43% 21%,  p=0.02 
269 pts, 
randomized 
prospective; 
6 mo 
angiographic 
and 2 years 
clinical FU 
MLD 2.59±0.43 
MLA 7.06±2.13 
 
MLD, 
2.96±0.55, p<0.001 
MLA 
7.78±1.72 
 
9-month FU 
CRUISE [12] 
2000 
No detailed IVUS 
criteria 
Post procedure IVUS analysis 
in the core lab 
TLR 
15.3% 
TLR 
8.5%, p< 0.05 
525 pts, 
multicenter 
prospective 
observational 
IVUS substudy 
IVUS-guided PTCA  Stent 
MLD 2.55±0.49 
MLA 6.60±2.05 
MLD 
2.75±0.49, p=0.013 
MLA 
7.28±2.22, p=0.02 
 
BEST [19] 
2003 
Balloon diameter 
closest to the vessel 
diameter (EEM mean 
diameter) 
IVUS criteria for crossover to 
stent: >30% stenosis or MLA< 
6 mm
2 
6-mo FU: no significant angiographic and MACE 
differences 
 
254 pts, 
multicenter, 
randomized 
MLD 2.46±0.46 
Acute gain 1.45±0.53 
MLA 7.16±2.48 
MLD 
2.57±0.41 
Acute gain 1.62±0.43, 
p=0.04 
MLA 
7.95±2.21, p=0.04 
6-months FU 
RESIST [23] 
1998 
 
Stent CSA>80% of the mean 
proximal and distal reference 
vessel CSA 
Only 77% of pts with adequate 
angiographic result satisfied 
IVUS criteria  Restenosis 28.8% 
MLA 4.47±2.59 
 
Restenosis 22.5%, p=0.25 
MLA 
5.36±2.81, p=0.03 
155 pts; 
multicenter, 
randomized, 
single-blinded 
MLD 2.91±0.41 
Acute gain 
1.91±0.66 
 
MLD 
3.02±0.49; p=0.01 
Acute gain 2.07±0.50; 
p<0.0001 
MLA 8.10±2.30 
6-months FU 
OPTICUS [24] 
2001 
 
MUSIC criteria for optimal 
stent implantation 
achieved in only 56% of 
patients  Binary restenosis 
22.8% 
Late loss 1.00±0.58 
 
Binary restenosis 
24.5%, p=0.68 
Late loss 1.07±0.62; 
p=0.20 
550 pts; 
multicenter, 
randomized IVUS-Guided Stent Implantation to Improve Outcome  Current Cardiology Reviews, 2009, Vol. 5, No. 2    81 
wo other prospective observational studies evaluated an 
IVUS-guided PTCA-provisional stenting strategy [20, 21]. 
Abizaid et al. [20] enrolled 280 patients, utilizing IVUS for 
balloon sizing (media-to-media diameter as a criterion) and 
identifying optimal PTCA results (65% of the mean 
proximal and distal reference lumen areas or 6.0 mm
2 and 
no dissection). At 1-year follow-up, TLR was necessary in 
8% of the PTCA group and 16% in the crossover to stent 
group. For this reason IVUS-guided aggressive PTCA was 
proposed as an alternative to routine elective stenting. In the 
study of Colombo et al.[21], 101 consecutive patients with 
long lesions were treated with IVUS-guided PTCA and spot 
stenting and confronted with a matched group of patients 
treated with traditional stenting. Also in this study, the 
balloon sizing was based on IVUS measurement of media-
to-media diameter, while optimal PTCA result was defined 
by MLD 5.5 mm
2 or 50% MVD at the lesion site. Spot 
stenting was performed only in the segments where the 
above criteria were not satisfied. The total stent length was 
significantly lower in the spot stenting group (10.4±13 mm 
vs.  32.4±13 mm in the matched group routinely stented, 
p<0.05) and associated with better long-term outcome (major 
adverse cardiac events [MACE] 22% vs. 38%, p<0.05 and 
angiographic restenosis 19% vs.34%, p<0.05).  
  IVUS guidance of stent implantation started being 
considered an effective aid in adequate stent expansion 
compared with angiographic guidance alone. This hypothesis 
was once again confirmed by the IVUS multicenter 
prospective observational substudy, Can Routine 
Ultrasound Influence Stent Expansion (CRUISE) [12], of 
the Stent Anti-thrombotic Regimen Study. The most 
important limitations of the CRUISE trial are that it lacked 
clear criteria for IVUS optimization and constituted part of a 
larger study. Nine centers were prospectively assigned to 
IVUS-guided stent deployment and 7 centers to angiographic 
guidance alone with documentary (blinded) IVUS at the 
conclusion of the procedure. The IVUS-guided group had a 
larger MLD (2.96±0.55 vs. 2.59±0.43, p<0.001) and a larger 
minimal stent CSA (7.78±1.72 vs. 7.0±62.13 mm2, 
p<0.001). At 9-months follow-up, TLR occurred signifi-
cantly less frequently in the IVUS-guided group (8.5% vs. 
15.3%, p<0.05; relative risk reduction of 44%). 
 De  Feyter  et al. [22] constructed with multivariate 
logistic regression analysis a reference chart to predict the 
expected in-stent restenosis (ISR) rate based on operator-
dependent IVUS parameters. In-stent MLA (inversely 
related) and stent length (directly related) were found to be 
the strongest predictors of ISR at 6 months, confirming once 
more the “bigger is better” doctrine, which were further 
confirmed in subsequent randomized trials on IVUS 
guidance. 
  The first randomized trial designed to support this 
hypothesis,  Restenosis after IVUS-guided Stenting 
(RESIST) study, was conducted in France by Schiele et al. 
[23]. Even though there was not a significant absolute 
reduction in the restenosis rate (6.3%; 28.8% vs. 22.5%, 
p=0.25), a difference in post-procedural MLD (2.46±0.46 in 
angiography vs. 2.57±0.41 in IVUS-guided group, p=0.11) 
and stent CSA (6.89±2.71 in angio vs. 7.17±2.48 in IVUS 
guided group, p=0.35) were observed in this study. Thus a 
beneficial effect of IVUS guidance could not be ruled out as 
a result of the small number of the patients included in the 
study (155) and the lack of statistical power. A significant 
increase in 6-month stent lumen CSA was observed 
(4.47±2.59 vs. 5.36±2.81 mm
2, p=0.03), indicating that 
IVUS guidance in stent deployment may be beneficial. In the 
multivariate logistic regression analysis, post-procedural 
stent CSA was the only predictor (inversely related) of 6-
months ISR (odds ratio 0.7, 95% CI 0.47-0.93, p=0.007). 
(Table 1). contd….. 
Results 
  Balloon Sizing (BS)  IVUS Criteria 
Angiographic IVUS 
Study Design 
MLD 2.80±0.31 
Acute gain 1.81±0.45 
MLD 3.01±0.40, p=0.008 
Acute gain 2.04±0.62, 
p=0.045 
MLA 6.00±3.30 
6-months FU  TULIP [25] 
2002 
 
1) complete stent apposition; 
2) MLD 80% of the mean of 
prox and distal reference 
diameters;  
3) MLA distal reference 
lumen area. 
Criteria accomplished in 89% 
of patients 
Binary restenosis 
46% 
Late loss 1.33±0.55 
TLR  
10% 
Binary restenosis 
23%, p=0.008 
Late loss 1.20±0.51, p=NS 
TLR  
3%, p=0.037 
150 pts, 
multicenter, 
randomized 
MLD 2.89±0.51 
MLA 6.90±2.43 
MLD  
2.95±0.49, p=0.15 
MLA  
7.55±2.82, p=0.001 
12 months FU 
AVID [26, 27] 
2000 
 
1. MLA 90% of distal 
minimal vessel lumen CSA; 
2. Stent fully apposed; 
3. Dissections covered by stent  
Criteria accomplished only in 
48% patients  TLR 10.1%  TLR 4.3%, p=0.01 
800 pts, 
multicenter 
randomized  
AVIO 
median vessel media-
to-media diameters at 
different sites in the 
stent segment 
AOR  
(see Table 2) 
ongoing multicenter randomized trial   
IVUS- intravascular ultrasound; MLD- minimal lumen diameter (mm), MLA- in stent minimal lumen area (mm
2); TLR- target lesion revascularization; FU- follow-up; EEM- 
external elastic membrane; AOR- achievable optimal result. 82    Current Cardiology Reviews, 2009, Vol. 5, No. 2  Rogacka et al. 
  Optimization with Intracoronary Ultrasound to 
Reduce Stent Restenosis (OPTICUS) [24] was a large 
multicenter study in which 550 patients were randomized to 
stent implantation with IVUS or angiographic guidance. The 
MUSIC study criteria were applied for optimal IVUS-guided 
stent implantation, even though these were achieved only in 
56% of patients and the mean stent area in the IVUS group 
was relatively low (8.1±2.3 mm
2). Six-months repeat 
angiography revealed no significant differences between the 
groups with respect to binary restenosis rates (24.5% vs. 
22.8%, p=0.68) and MLD (1.95±0.72 vs. 1.91±0.68 mm, 
p=0.52), respectively in the IVUS and angiography-guided 
groups. At 12 months, neither MACE (relative risk [RR], 
1.07; 95% CI 0.75-1.52; p=0.71) nor repeat revascularization 
(RR 1.04; 95% CI 0.64 to 1.67; p=0.87) were reduced in the 
IVUS-guided group. The authors concluded that the study 
does not support routine use of IVUS to guide coronary 
stenting and the additional procedural costs incurred with 
IVUS may be saved without exposing patients to excessive 
risks. However, this conclusion should be interpreted taking 
into consideration the low percentage of procedures with 
optimal stent implantation according to established IVUS 
criteria. 
  Contrary conclusions, i.e. improved clinical and 
angiographic outcome in patients treated with IVUS-guided 
stent implantation, were drawn from the Thrombocyte 
Activity Evaluation and Effects of Ultrasound Guidance 
in Long Intracoronary Stent Placement (TULIP) study 
[25]. In this multicenter randomized trial, long lesions (20 
mm) were analyzed. The IVUS optimization criteria were 
slightly less aggressive in comparison with the MUSIC trial 
(See Table 1) and were reached in 89% of patients. 
Significant differences were documented between the groups 
in favor of IVUS-guided stent implantation: greater final 
MLD (3.01±0.40 vs. 2.80±0.31 mm, p=0.008) and acute gain 
(2.04±0.62 vs. 1.81±0.45mm, p=0.045), lower binary 
restenosis rate at 6-months angiographic follow-up (23% vs. 
46%, p=0.0082) and a subsequent decrease in TLR (4% vs. 
14%, p=0.037). Despite MLD at follow-up being 
significantly larger in the IVUS group (1.82±0.53 vs. 
1.51±0.71, p=0.042), there was no difference in late loss 
(1.20±0.51 vs. 1.33±0.55 in the angiography-guided group, 
p=NS).  
  The Angiography Versus Intravascular Ultrasound- 
Directed (AVID) [26, 27] trial was the largest multicenter 
randomized study (800 patients) that showed a significant 
clinical and angiographic benefit of IVUS-guided stenting 
over angiographic evaluation alone. The first attempt to 
simplify the IVUS criteria for optimal stent placement was 
done, in order that these criteria could be applied in everyday 
interventional practice (see Table 1). However, according to 
these criteria, stents were optimally implanted only in 48% 
of cases. Moreover, only 37% of patients who did not meet 
IVUS criteria received an additional treatment (e.g. 
postdilatation for an underexpanded stent). Final stent MLA 
was 6.90±2.43 mm
2 in the angiography group and 7.55±2.82 
mm
2 in the IVUS group (p=0.001), results which are 
comparable with previous reports (see Table 1). After 
excluding all the lesions with diameter <2.5 mm, a 
significant reduction in TLR was observed in the IVUS 
group at 12 months follow-up (4.3% vs. 10.1%; p=0.01). 
Apart from an evident advantage of IVUS guidance over 
angiography alone in obtaining larger MLD, thus decreasing 
the need of repeat revascularization, this study raised an 
important problem of underutilization of IVUS information 
due to both the lack of experience in evaluating IVUS 
images by an operator (discrepancy between the 
measurements done during the procedure and off-line) and a 
concern about postdilation with larger diameter balloons at 
higher pressures. 
  The IVUS studies in the BMS era provided critical 
insights into the pathophysiology of subacute stent 
thrombosis and contributed to the modern idea of IVUS 
optimization of stent implantation. However, despite 
numerous attempts, no uniform criteria were established for 
an appropriate IVUS-guided PTCA. Postdilatation was not a 
standard step after stent implantation and, if performed, the 
balloon diameter was chosen on the basis of complicated 
numerical formulas derived from IVUS measurements. In 
fact, only in a small percentage of the patients treated in the 
above studies, an adequate postdilatation was performed. 
Moreover, the IVUS criteria for optimal stent implantation 
were detailed only in the MUSIC trial (used also in the SIPS 
and OPTICUS studies). All the other studies utilized less 
complex criteria, which contributed to simplification of the 
procedure but resulted in inappropriate stent postdilatation. 
Moreover, even simplified criteria of IVUS optimization 
were satisfied only in small percentage of patients, which 
once again confirms the hypothesis that theoretically 
acceptable definitions may be inapplicable in everyday 
practice.  
  The question of adequate stent implantation becomes 
even more important with DES, especially in the era of 
complex, multivessel and/or left main coronary artery 
stenting. IVUS should unquestionably help the operator to 
minimize the risk of stent thrombosis resulting from stent 
malapposition or underexpansion. To obtain this, simple and 
easily applicable criteria which do not influence negatively 
the time of the procedure need to be elaborated.  
IVUS-Guided Stenting in the DES Era 
  With the introduction of DES the rate of restenosis has 
been significantly reduced but a new concern, the risk of 
stent thrombosis has emerged. Small observational studies 
demonstrated the association of stent underexpansion with 
stent thrombosis in BMS [6, 7, 28, 29]. Alfonso et al. [30] 
documented severe stent malapposition in 4 out of 12 
patients (33%) presenting with stent thrombosis in BMS. 
The MUSIC criteria for IVUS optimization were not 
satisfied in any of them during the index procedure and the 
stent expansion varied from 41% to 71% (MLA 3.3 to 7.8 
mm
2).  
  The past two years have highlighted concerns regarding 
the safety and efficacy of DES, in particular the increased 
risk of stent thrombosis and the associated morbidity and 
mortality [7, 31]. An angioscopic study by Kotani et al. [32], 
demonstrated that more unepithelialized stent struts could be 
found after DES implantation compared to with BMS at 6 
months follow-up. Even though the exact mechanism of 
thrombus formation in DES is still being investigated, 
inadequate apposition of the stent within the coronary artery 
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thrombogenesis. The definition and pathogenesis of 
malapposition needs to be clarified for a better understanding 
of its clinical significance and importance. Incomplete stent 
apposition (ISA) or stent malapposition is the IVUS finding 
of lack of contact between stent struts, not overlying a side 
branch, and the underlying arterial wall [28]. Late ISA can 
either be due to persistence of acute ISA occurring at the 
time of stent implantation or late-acquired ISA occurring 
between stent implantation and follow-up. Traditionally the 
term “Late ISA” has mainly been used to describe late-
acquired ISA. Acute ISA is mostly technique dependant and 
may be due to suboptimal stent implantation or by severely 
calcified lesions not allowing for homogeneous stent 
expansion and resulting in localized stent underexpansion 
and ISA [6, 33]. In contrast, the pathogenesis of late ISA 
includes: a) positive arterial remodelling so that the vessel 
pulls away from the stent; b) dissolution of plaque and 
thrombus behind the stent, so that a gap forms between the 
stent and vessel wall; and c) chronic stent recoil [6, 33, 34]. 
While there does appear to be a link between acute ISA and 
early (acute and subacute) stent thrombosis, the link between 
late ISA and late stent thrombosis is not that clear. Late ISA 
is common, occurring in 10-20% of DES [6, 29, 34], and the 
majority of late ISA detected on IVUS is not associated with 
clinical events [28]. As acute malapposition (and underex-
pansion) are technique-dependant they are correctable if 
found on IVUS during the procedure. In late-acquired ISA, 
on the other hand, the post-intervention IVUS demonstrates 
complete stent apposition and there are no specific factors 
IVUS that would predict that ISA will develop during the 
follow-up period. Hong et al. [34] observed that ISA 
occurred in up to 12% of cases of DES implantation, and 
was more frequent in long stents, chronic total occlusions 
and stenting during acute myocardial infarction. According 
to Okabe et al. [35], small stent CSA (<4.6mm
2) and residual 
disease at stent edges were also predictors of stent 
thrombosis.  
 Waksman  et al. [36] recently published the data from the 
largest registry on IVUS-guided PCI with DES. The 
outcomes in 884 patients (1296 lesions) who underwent 
IVUS-guided DES implantation to all treated lesions were 
compared with those in 884 propensity-score matched 
patients (1312 lesions) who underwent DES implantation 
with angiographic guidance alone. At 30 days and at 12 
months, a higher rate of definite stent thrombosis was seen in 
the No-IVUS group (0.5 vs. 1.4%; p = 0.046) and (0.7 vs. 
2.0%; p = 0.014, respectively). There were no major 
differences in late stent thrombosis and MACE (14.5 vs. 
16.2%; p = 0.33) at 12 month follow-up between the groups. 
Rates of death and myocardial infarction were similar. A 
trend was seen in favor of the IVUS group in TLR (5.1 vs. 
7.2%; p=0.07). IVUS guidance was an independent predictor 
of freedom from cumulative stent thrombosis at 12 months 
(adjusted hazard ratio = 0.5, 95% CI 0.1–0.8; p = 0.02). 
  Further randomized studies are necessary to establish the 
exact role of late malapposition in thrombogenesis and 
IVUS-guided optimal stent expansion in reducing binary 
restenosis and need of repeat revascularization [28].  
  The introduction of virtual histology intravascular 
ultrasound (VH-IVUS) may provide new information about 
the composition of the plaque, correlating it to angiographic 
and clinical events associated with stent implantation. 
Kawaguchi et al. [37] found VH-IVUS useful in predicting 
the risk of distal embolization, assessed as ST-segment re-
elevation (STR), after stent implantation during primary 
angioplasty. Necrotic core volume was significantly higher 
in the STR group (32.9±14.1 mm
3) than in the non-STR 
group (20.4±19.1 mm
3; p<0.05). The similar findings but in 
a non-acute onset were reported in the paper of Kawamoto et 
al. [38]. The liberation of small embolic components form 
the necrotic core of the plaque detected and quantified with 
VH-IVUS, resulted in poorer recovery of coronary flow 
velocity reserve. However, the clinical utility of VH-IVUS in 
preventing clinical events still remains to be proven. 
MODERN IVUS CRITERIA 
  A wide variety of non-uniform IVUS criteria for the 
optimization of stent implantation has resulted in a large 
variability in the frequency of achieving various IVUS 
criteria based on differences in vessel size, plaque burden, 
and balloon-to-artery ratio, as pointed out by Moussa et al. 
[39]. According to their evaluation of 425 patients, achieving 
in-stent MLA90% of distal reference MLA did not lead to a 
reduction in restenosis, while reaching an MLA9 mm
2 was 
associated with a low restenosis rate. This criterion, 
however, was primarily accomplished in large vessels. 
Moreover, in-stent MLA55% of average reference vessel 
CSA predicted a higher probability of freedom from 
restenosis independently from vessel size. The restenosis rate 
was lower (11%) with MLA9mm
2 and reached 27% with 
lower MLAs. 
  Universal and easily applicable IVUS criteria for 
optimization of stent implantation could resolve, or at least 
minimize, the problems of stent malapposition and 
underexpansion, which in turn could positively influence the 
rates of stent restenosis and thrombosis. Until now, the 
criteria for IVUS optimization used in different studies have 
relied on distal reference or on mean reference vessel for 
stent or postdilatation balloon sizing. This reduces the 
potential to optimally increase the lumen size particularly in 
long lesions with overlapping stents and in vessels with 
distal tapering. Also the actual results and differences in final 
MLD achieved with IVUS compared to angiographic 
guidance have been small in previous studies. Furthermore, 
an important recent innovation not available in previous 
studies that may be having a significant contribution to 
optimal stent implantation is the use of noncompliant 
balloons to perform high pressure postdilatation. Up to now, 
there is no randomized study on IVUS-guided DES 
implantation. Consequently, IVUS guidance has played a 
limited role in the current clinical practice due a lack of clear 
demonstrable clinical benefit. 
  Our group is presently supporting the effort to establish 
modern, universal criteria for IVUS optimization of stent 
implantation. Our hypothesis is that IVUS guided stent 
implantation with modern noncompliant balloons and better 
criteria for optimal stent expansion would result in an 
immediate result of better stent expansion that will translate 
into a long-term clinical benefit. The Angiographic Versus 
IVUS Optimization (AVIO) multicenter randomized study, 
designed by our group, may provide important insights into 
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DES era. The aim of the study is to determine whether 
IVUS-guided DES implantation in complex lesions is 
superior to angiographically-guided implantation in 
improving post-procedural minimum lumen diameter (MLD) 
as the primary endpoint. The study uses modern criteria for 
IVUS optimization based on the achievement of a CSA 
inside the stent corresponding to the area achieved in our 
preliminary experience, called the achievable optimal result 
(AOR) in Table 1. The AOR depends on the diameter of the 
optimal postdilatation balloon chosen based on the vessel 
media-media size at different points. These criteria take into 
account the varying vessel size in overlapping stents and that 
multiple post-dilations with different size non-compliant 
balloons may be needed. The flow chart for the AVIO study 
has been summarized in Fig. (1). 
  We assessed the safety and feasibility of these criteria in 
a pilot study, PRAVIO: (Preliminary Investigation to the 
Angiographic Versus IVUS Optimization Trial). For this 
study, we defined optimization as achieving  70% of the 
CSA of the post-dilation balloon.  
  The size of this balloon was calculated using the median 
vessel media-to-media diameters at different sites in the stent 
segment. The CSA of the stent was measured at the most 
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narrowed zones and stent underexpansion was defined as 
CSA below 70% of the postdilating balloon that matched the  
median vessel-vessel diameter at the underexpanded zone. 
The stent was then postdilated with a non-compliant balloon 
at any site where the stent CSA was below the 70% criteria, 
and if needed several different sized balloons were used in  
 
Table 2.   AVIO Study Criteria for Optimal DES Implantation 
Based on - Achievable Optimal Result (AOR) is the 
Target Minimum Stent Cross-Sectional Area (CSA) 
According to the Non-Compliant Balloon Chosen for 
Postdilatation. The Diameter of the balloon is chosen 
on the basis of the average Media-to-Media 
Diameters of the Vessel at Different Points of the 
Stented Area (Proximal, Mid Lesion, Distal and any 
other Points of Interest such as Point of Maximum 
Underexpansion) 
Balloon Size (mm)  Achievable Optimal Result (mm
2) 
2.25 3.5 
2.5 4 
3 6 
3.5 8 
4 10 
4.5 12 
 
long-overlapping stents where the vessel diameter varied in 
size. Using these criteria, we were able to achieve a minimal 
stent CSA  70% of the postdilation balloon in 78% of 
lesions that underwent IVUS optimization. We then 
compared the final MLD in 93 IVUS optimized lesions with 
a group of angiographically-guided lesions matched 
according to diabetes, vessel type, reference vessel diameter 
(RVD), MLD and lesion length. Baseline RVD, MLD and 
lesion lengths were not statistically different between the two 
matched groups. However, final MLD was significantly 
larger in the IVUS compared to the angiographic guided 
group (3.09 ± 0.50 v 2.67 ± 0.54; p < 0.0001). From a 
practical point of view, we noted that despite a similar 
baseline angiographic RVD, the use of IVUS gave the 
operator the confidence to select a larger postdilating balloon 
size (3.26 ± 0.50 vs. 2.98 ± 0.42 mm; p<0.001) and safely 
inflate the balloon to higher pressures (24.4 ± 4.6 vs. 16.1 ± 
5.0 atmospheres; p<0.001), Fig. (2).  
  Interestingly, from this pilot study we found that using 
the “>70% CSA of postdilating balloon” criteria was an 
underestimation of the actual result that we were achieving 
and thus redefined our AOR. Thus for the randomized AVIO 
trial, the criteria that will be utilized (Table 2), uses the AOR 
we found in this pilot study. 
CONCLUSIONS 
  The search for clear and uniform criteria for IVUS 
optimization is still ongoing, especially in the DES era. Even 
more importantly, whether IVUS-guided DES implantation 
will have benefits on clinical outcomes remains unproven. 
The growing need to lower the risk of DES thrombosis and 
restenosis coupled with the treatment of more complex 
lesions may give IVUS-guided stenting another opportunity 
to prove itself. The results and clinical applicability of the 
AVIO trial to routine clinical practice may shed some light 
on whether the promise of IVUS-guided stent implantation 
has a role in the DES era. 
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